Coronavirus - COVID 19 HAS veille
40.3K views | +53 today
Follow
Coronavirus - COVID 19 HAS veille
Your new post is loading...
Scooped by HAS-veille
Scoop.it!

Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies.

Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies. | Coronavirus - COVID 19 HAS veille | Scoop.it
Dufloo et al. show that SARS-CoV-2 infection elicits antibodies that neutralize the
virus, activate the complement system and kill infected cells by ADCC. These polyfunctional
antibodies are slightly more abundant in symptomatic COVID-19 patients than in asymptomatic
individuals and correlate with disease severity.
HAS-veille's insight:

étude française Inserm / Institut Pasteur / CNRS

No comment yet.
Scooped by HAS-veille
Scoop.it!

ComCor : résultats et analyse critique sur l'étude sur les lieux et les circonstances de transmission du SARS-CoV-2

ComCor : résultats et analyse critique sur l'étude sur les lieux et les circonstances de transmission du SARS-CoV-2 | Coronavirus - COVID 19 HAS veille | Scoop.it
ComCor est une vaste étude qui inclut plus de 160 000 participants* avec infection aiguë par le SARS-CoV-2. Elle permet de décrire les lieux et les circonstances de contamination par le ce virus. Retour sur l’intérêt et les limites de l’étude ComCor, ou ce que l’on peut retenir de ses résultats.*19 avril 2021
No comment yet.
Scooped by HAS-veille
Scoop.it!

 Vaccins COVID-19 : l’ANSM met en place un comité d’experts hebdomadaire sur les effets thrombotiques - ANSM

 Vaccins COVID-19 : l’ANSM met en place un comité d’experts hebdomadaire sur les effets thrombotiques - ANSM | Coronavirus - COVID 19 HAS veille | Scoop.it
Vaccins COVID-19 : l’ANSM met en place un comité d’experts hebdomadaire sur les effets thrombotiques
No comment yet.
Scooped by HAS-veille
Scoop.it!

Covid-19: What do we know about airborne transmission of SARS-CoV-2? | The BMJ


No comment yet.
Scooped by HAS-veille
Scoop.it!

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM | Coronavirus - COVID 19 HAS veille | Scoop.it
Abstract Background The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus
No comment yet.
Scooped by HAS-veille
Scoop.it!

Post-acute COVID-19 outcomes in children with mild and asymptomatic disease

Post-acute COVID-19 outcomes in children with mild and asymptomatic disease | Coronavirus - COVID 19 HAS veille | Scoop.it
Data on the clinical outcomes of children with COVID-19 are scarce, particularly in
those with asymptomatic and mild disease.1,2 Studies involving adults suggest that
long-term multisystem sequelae and complications can occur, even with mild COVID-19.3
We aimed to describe medium-term clinical outcomes 3–6 months after diagnosis in children
with COVID-19 presenting to a tertiary paediatric hospital.
No comment yet.
Scooped by HAS-veille
Scoop.it!

Covid-19, Circonstances de contamination et mesures de prévention

Covid-19, Circonstances de contamination et mesures de prévention | Coronavirus - COVID 19 HAS veille | Scoop.it
Site ORS
No comment yet.
Scooped by HAS-veille
Scoop.it!

ECDC guidance for adjusting non-pharmaceutical interventions based on vaccination status

ECDC guidance for adjusting non-pharmaceutical interventions based on vaccination status | Coronavirus - COVID 19 HAS veille | Scoop.it
Interim guidance on the benefits of full vaccination against COVID-19 for transmission and implications for non-pharmaceutical interventions.
No comment yet.
Scooped by HAS-veille
Scoop.it!

Interim guidance on the benefits of full vaccination against COVID-19 for transmission and implications for non-pharmaceutical interventions

Interim guidance on the benefits of full vaccination against COVID-19 for transmission and implications for non-pharmaceutical interventions | Coronavirus - COVID 19 HAS veille | Scoop.it
This document aims to provide interim guidance on the risks for fully vaccinated individuals to develop or transmit
infection that will give rise to severe COVID-19 disease in the context of the current epidemiological and vaccine
coverage situation in the EU/EEA.
No comment yet.
Scooped by HAS-veille
Scoop.it!

A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development | ACS Central Science

The prior year has seen an unprecedented number of vaccine candidates directed at the COVID-19 pandemic. This report examines these vaccines and the related research effort, both traditional and forward-looking, to illustrate the advantages and disadvantages of their technologies, to denote the use of adjuvants and delivery systems in their application, and to provide a perspective on their future direction.
No comment yet.
Scooped by HAS-veille
Scoop.it!

COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room

COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room | Coronavirus - COVID 19 HAS veille | Scoop.it
Approximately 96 COVID-19 vaccines are at various stages of clinical development.1
At present, we have the interim results of four studies published in scientific journals
(on the Pfizer–BioNTech BNT162b2 mRNA vaccine,2 the Moderna–US National Institutes
of Health [NIH] mRNA-1273 vaccine,3 the AstraZeneca–Oxford ChAdOx1 nCov-19 vaccine,4
and the Gamaleya GamCovidVac [Sputnik V] vaccine)5 and three studies through the US
Food and Drug Administration (FDA) briefing documents (on the Pfizer–BioNTech,6 Moderna–NIH,7
and Johnson & Johnson [J&J] Ad26.COV2.S vaccines).
No comment yet.
Scooped by HAS-veille
Scoop.it!

COVID-19 Vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets

COVID-19 Vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets | Coronavirus - COVID 19 HAS veille | Scoop.it
COVID-19 Vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low platelets
No comment yet.
Scooped by HAS-veille
Scoop.it!

Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study

Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study | Coronavirus - COVID 19 HAS veille | Scoop.it
The lower than expected immune responses, especially in the older age groups, and
the high reactogenicity after dose two were probably due to higher than anticipated
host-cell protein content and lower than planned antigen doses in the formulations
tested, which was discovered during characterisation studies on the final bulk drug
substance. Further development of the AS03-adjuvanted candidate vaccine will focus
on identifying the optimal antigen formulation and dose.
No comment yet.
Scooped by HAS-veille
Scoop.it!

SARS-CoV-2 : l’infection induit des anticorps capables de tuer les cellules infectées quelle que soit la sévérité de la maladie

SARS-CoV-2 : l’infection induit des anticorps capables de tuer les cellules infectées quelle que soit la sévérité de la maladie | Coronavirus - COVID 19 HAS veille | Scoop.it
[:fr]  En s’appuyant sur des études épidémiologiques de terrain et sur la cohorte hospitalière FrenchCOVID coordonnée par l’Inserm, des équipes de l’Institut Pasteur, du CNRS et
No comment yet.
Scooped by HAS-veille
Scoop.it!

AP-HP - Essai CAMOVID pour évaluer les effets du camostat mesylate dans le traitement de l'infection COVID-19 chez des patients ambulatoires risquant une évolution vers une forme sévère. | APHP

AP-HP - Essai CAMOVID pour évaluer les effets du camostat mesylate dans le traitement de l'infection COVID-19 chez des patients ambulatoires risquant une évolution vers une forme sévère. | APHP | Coronavirus - COVID 19 HAS veille | Scoop.it
No comment yet.
Scooped by HAS-veille
Scoop.it!

 Annales de Biologie Clinique - Tests rapides antigéniques SARS-CoV-2 : définition, législation d’utilisation, principes technologiques, comparaison des performances analytiques...

 Annales de Biologie Clinique - Tests rapides antigéniques SARS-CoV-2 : définition, législation d’utilisation, principes technologiques, comparaison des performances analytiques... | Coronavirus - COVID 19 HAS veille | Scoop.it
No comment yet.
Scooped by HAS-veille
Scoop.it!

Vaccine Breakthrough Infections with SARS-CoV-2 Variants | NEJM

Vaccine Breakthrough Infections with SARS-CoV-2 Variants | NEJM | Coronavirus - COVID 19 HAS veille | Scoop.it
Summary Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are of clinical concern. In a cohort of 417 persons who had received the second dose of BNT162b
No comment yet.
Scooped by HAS-veille
Scoop.it!

Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons | NEJM

Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons | NEJM | Coronavirus - COVID 19 HAS veille | Scoop.it
Abstract Background Many pregnant persons in the United States are receiving messenger RNA (mRNA) coronavirus disease 2019 (Covid-19) vaccines, but data are limited on their safety in pregnancy
No comment yet.
Scooped by HAS-veille
Scoop.it!

COVID vaccines and kids: five questions as trials begin

COVID vaccines and kids: five questions as trials begin | Coronavirus - COVID 19 HAS veille | Scoop.it
As the first clinical trials in young children start, here's what scientists want to know.
No comment yet.
Scooped by HAS-veille
Scoop.it!

Covid-19: Canada relaxes age limits on AstraZeneca vaccine as Ontario cases surge | The BMJ

No comment yet.
Scooped by HAS-veille
Scoop.it!

FDA Announces New Streamlined Approach to Add Pooled Serial Screening Claims to Certain Authorized Tests for Use in Serial Testing Programs | FDA

FDA Announces New Streamlined Approach to Add Pooled Serial Screening Claims to Certain Authorized Tests for Use in Serial Testing Programs | FDA | Coronavirus - COVID 19 HAS veille | Scoop.it
FDA announces streamlined EUA amendment for certain molecular test developers to pool specimens as part of a serial testing program.
No comment yet.
Scooped by HAS-veille
Scoop.it!

Amplification-free RNA detection with CRISPR–Cas13

Amplification-free RNA detection with CRISPR–Cas13 | Coronavirus - COVID 19 HAS veille | Scoop.it
CRISPR-based nucleic-acid detection is an emerging technology for molecular diagnostics. However, these methods generally require several hours and could cause amplification errors, due to the pre-amplification of target nucleic acids to enhance the detection sensitivity. Here, we developed a platform that allows “CRISPR-based amplification-free digital RNA detection (SATORI)”, by combining CRISPR-Cas13-based RNA detection and microchamber-array technologies. SATORI detected single-stranded RNA targets with maximal sensitivity of ~10 fM in <5 min, with high specificity. Furthermore, the simultaneous use of multiple different guide RNAs enhanced the sensitivity, thereby enabling the detection of the SARS-CoV-2 N-gene RNA at ~5 fM levels. Therefore, we hope SATORI will serve as a powerful class of accurate and rapid diagnostics. The authors develop a platform (SATORI) that enables accurate and rapid detection of single-stranded RNA at a single-molecule level without a pre-amplification step. As a proof-of-concept, they demonstrate its utility in detecting the SARS-CoV-2 N gene at a minimum concentration of ~5 fM, which is much lower than other amplification-free CRISPR-Cas-based methods.
No comment yet.
Scooped by HAS-veille
Scoop.it!

How COVID hurt the fight against other dangerous diseases

How COVID hurt the fight against other dangerous diseases | Coronavirus - COVID 19 HAS veille | Scoop.it
Campaigns to battle tuberculosis, measles and polio have all been set back.
No comment yet.
Scooped by HAS-veille
Scoop.it!

Long COVID’s long R&D agenda

Long COVID’s long R&D agenda | Coronavirus - COVID 19 HAS veille | Scoop.it
As researchers work to understand the biology and epidemiology of post-acute COVID-19, a pioneering platform trial is now testing treatments to try to address the long-term complications of infection in previously hospitalized individuals.
No comment yet.
Scooped by HAS-veille
Scoop.it!

Projection à court terme des besoins hospitaliers - Modélisation COVID-19

Les analyses présentées sur ce site permettent par exemple d’estimer les risques associés à l’infection SARS-CoV-2, d’évaluer l’impact des mesures de contrôle, de suivre la diffusion du virus SARS-CoV-2, en estimant par exemple la proportion de la population ayant été infectée par le SARS-CoV-2, de produire des projections pour anticiper sur le court terme les besoins hospitaliers des patients COVID-19, et de caractériser la course qui s’annonce entre vaccins et variants.
No comment yet.